Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

Diagnostics & Research is Zen Rated C and is the 68th ranked industry out of 145 stock market industries

Ticker	Company	DD Score	Valuation Score	Financials Score	Forecast Score	Dividends Score
QGEN	QIAGEN NV	25	14	57	56	0
FONR	FONAR CORP	39	71	86	0	–
ILMN	ILLUMINA INC	20	0	57	22	–
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	14	14	43	0	–
DHR	DANAHER CORP	31	14	57	44	40

Upgrade to Premium to View More

Use Due Diligence Score to quickly analyze stock fundamentals, even if you don't have a finance background. We run time-tested due diligence checks inspired by legendary investors like Warren Buffett, and score each company based on how many they pass/fail.

Already have a premium account?

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jun 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 25, which is -2 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 10 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock return 8.67% over the past year, overperforming other diagnostic & research stocks by 32 percentage points.

Qiagen Nv has an average 1 year price target of $46.33, a downside of -1.65% from Qiagen Nv's current stock price of $47.11.

Qiagen Nv stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Qiagen Nv, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 12 points higher than the diagnostic & research industry average of 27.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -3% over the past year, overperforming other diagnostic & research stocks by 20 percentage points.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 20, which is -7 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 6 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -20.41% over the past year, overperforming other diagnostic & research stocks by 3 percentage points.

Illumina has an average 1 year price target of $105.20, an upside of 21.02% from Illumina's current stock price of $86.93.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.28%, which is 1 percentage points higher than the diagnostic & research industry average of 0.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.83%, which is the same as the diagnostic & research industry average of 0.61%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.61%, which is the same as the diagnostic & research industry average of 0.61%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.8% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.73% in the last day, and up 0.1% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -54.18% in the past year. It has underperformed other stocks in the diagnostic & research industry by -31 percentage points.

2. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has dropped -29.66% in the past year. It has underperformed other stocks in the diagnostic & research industry by -7 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -3% in the past year. It has overperformed other stocks in the diagnostic & research industry by 20 percentage points.

Are diagnostic & research stocks a good buy now?

47.62% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 17.5% over the next year.

4.88% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 4.88% of diagnostic & research stocks are rated B (Buy), 70.73% are rated C (Hold), 19.51% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 19.9x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.